PKM2 AP micropeptide as molecular glue: a new paradigm for vascular calcification therapy

The metabolic baseline: why PKM2 became a vascular calcification target

Vascular calcification is not passive mineral deposition but an active osteogenic transition of vascular smooth muscle cells, accompanied by a metabolic shift from oxidative phosphorylation toward aerobic glycolysis and lactate accumulation [1][2]. This reprogramming is now recognized as a central driver of atherosclerotic plaque heterogeneity and instability, with key regulators including glucose transporters, PDK4, PFKFB3, and PKM2 integrating extracellular stimuli into VSMC fate decisions [2]. PKM2, the rate-limiting glycolytic enzyme catalyzing the final step of glycolysis, had been implicated in synthetic VSMC phenotypes, but its direct regulatory role in calcification remained unclear before this study [1]. The broader micropeptide field had already established that small open reading frames within long noncoding RNAs, circular RNAs, and mitochondrial DNA encode functional peptides that regulate metabolism, immune response, and cardiovascular pathology [3][8]. What was missing was a specific micropeptide connecting these two lines of inquiry.

PKM2 AP: from intron-retaining transcript to molecular glue

The anchor study identified PKM2 AP as a 40-amino-acid micropeptide encoded by an ORF2-containing intron-retaining transcript derived from the LINC01139 locus, localizing to both mitochondrial and cytoplasmic compartments [1]. Immunoprecipitation-mass spectrometry identified PKM2 as the top interacting partner by peptide coverage, and co-immunoprecipitation confirmed direct physical interaction [1]. Functionally, PKM2 AP overexpression decreased PKM2 protein without changing mRNA levels, and the proteasome inhibitor MG132 completely abolished this reduction, establishing ubiquitin-proteasome-dependent degradation [1]. Mechanistically, PKM2 AP stabilizes a ternary complex between PKM2 and the E3 ubiquitin ligase STUB1, inducing K48-linked polyubiquitination at lysine 136 of PKM2 [1]. This molecular glue-like action is notable because it achieves what synthetic glues are being designed to do: recruit an E3 ligase to a target protein for degradation [4]. The study used molecular docking, molecular dynamics simulations, co-immunoprecipitation, and surface plasmon resonance to support this mechanism, though direct structural characterization of the ternary complex was not performed [1].

Functional consequences: glycolysis suppression and calcification attenuation

PKM2 AP-mediated degradation of PKM2 suppressed aerobic glycolysis and lactate production in HEK 293T cells, as measured by extracellular acidification rate, glycolytic proton efflux, and intracellular lactate quantification [1]. In human aortic vascular smooth muscle cells, PKM2 AP treatment reduced calcium deposition and alkaline phosphatase activity while downregulating the osteogenic markers RUNX2 and BMP2 [1]. The PKM2-specific inhibitor PKM2-IN-1 produced concordant effects in vitro and in a vitamin D-induced mouse calcification model, reducing calcification area and osteogenic marker expression in aortic tissue [1]. In vivo administration of PKM2 AP and genetic knock-in of ORF2 both alleviated vascular calcification phenotypes in mice [1]. These findings align with earlier evidence that STUB1 can degrade PKM1/2 via the ubiquitin-proteasome system, as demonstrated in hyperthermia-resistant ovarian cancer cells where STUB1 upregulation led to PKM1/2 degradation and glycolytic suppression [5]. The convergence across different cell types and disease contexts strengthens the generalizability of the STUB1-PKM2 degradation axis.

How this fits with competing approaches and precursor evidence

The molecular glue concept has been most actively pursued in oncology, where CRBN-based glues selectively degrade VAV1 by recognizing a non-canonical RT-loop degron, a mechanism distinct from the canonical G-loop paradigm [4]. That work used AI-driven protein folding and high-throughput proteomics to design synthetic glues, whereas PKM2 AP is an endogenous micropeptide that achieves target degradation without chemical synthesis [1][4]. This distinction matters for therapeutic development: synthetic glues require optimization of drug-like properties, while peptide-based approaches face challenges of stability, delivery, and bioavailability [7][8]. The micropeptide field has also identified other cardiovascular-relevant peptides, such as MOTS-c, which alleviates vascular calcification in rats through AMPK signaling activation [8]. MOTS-c is mitochondria-derived and acts through a different mechanism, suggesting that multiple micropeptide pathways converge on vascular calcification regulation. The precursor review on noncoding RNA-encoded micropeptides emphasized that post-translational modifications of micropeptides, including ubiquitination, are a promising but underexplored direction [3], and PKM2 AP provides a concrete example of a micropeptide functioning within the ubiquitin system.

Boundaries of the claim: what remains unvalidated

The study's limitations are explicitly acknowledged: the vitamin D-induced calcification model does not fully recapitulate CKD-associated vascular calcification in humans, and validation in uremic or hereditary CKD models is needed [1]. Direct structural characterization of the PKM2 AP-PKM2-STUB1 ternary complex by cryo-electron microscopy, X-ray crystallography, or FRET was not performed, leaving the molecular details of the glue interface unresolved [1]. Clinical cohort analyses correlating PKM2 AP expression with calcification severity in CKD patients are absent, and delivery strategies for peptide drugs or gene editing remain unexplored [1]. The broader peptide therapeutics field faces persistent challenges in stability, delivery, and resistance, with only two of thirty-one peptide-based cancer drugs demonstrating signaling inhibition [7]. Mitochondria-derived peptides similarly suffer from low bioavailability, poor stability, and high synthesis costs [8]. The micropeptide cancer literature notes that while expression levels of specific micropeptides correlate with prognosis, challenges in stability and delivery limit therapeutic translation [6]. Whether PKM2 AP can overcome these barriers for vascular calcification remains an open question.

About These Sources

This research page is built on 8 peer-reviewed studies — published from 2021 to 2026, 7 from 2024 or later, collectively cited 60 times — selected as the most relevant from 9 studies that passed quality screening, drawn from 83 papers retrieved from a database of over 500 million.

Sources used in this answer